Hepatitis C Virus Non-Structural protein, Genotype 4
recombinant, E. coli
For in vitro use only!
Shipping: shipped on blue ice
Storage Conditions: store at -20 °C
avoid freeze/thaw cycles
Shelf Life: 12 months
Purity: > 95 % (SDS-PAGE, RP-HPLC)
Form: liquid (Supplied in 50 mM Tris-HCL pH 8.0 and 5 mM EDTA)
The protein contains the HCV-NS5 genotyp 4 immunodominant region. Hepatitis C Virus NS5 protein is purified by proprietary chromatographic techniques.
Background: The hepatitis C virus (HCV) NS5A gene product is a phosphorylated 56 to 58 kDa nonstructural protein that displays a multitude of activities related to enhancement of viral pathogenesis. Although associated with other viral encoded proteins as part of the viral replicase complex positioned on the cytoplasmic side of the endoplasmic reticulum, a role for NS5A in viral replication has not been defined. Truncated versions of NS5A can act as transcriptional activators, while other recently characterized interactions of NS5A with cellular proteins indicate its pleiotropic role in HCV-host interactions. It has been shown that NS5B is a membraneassociated protein, which contains a C-terminal domain comprising 21 hydrophobic amino acids that is responsible for membrane anchorage. NS5B may form a complex with cellular proteins or other HCV nonstructural proteins, including NS3, the viral protease and helicase; NS4A, a cofactor of NS3 protease activity; and NS5A, a phosphoprotein containing a putative interferon sensitivity region. Although the HCV replication mechanism is not clearly understood, the essential role of NS5B polymerase in the HCV replication and infection process has been demonstrated in chimpanzees. Accordingly, it has been viewed as an attractive target for antiviral intervention.
Antigen in ELISA and Western blots, excellent antigen for detection of HCV with minimal specificity problems.
Specificity: Immunoreactive with sera of HCV-infected individuals.
Kalliampakou et al. (2005) Hepatitis C virus (HCV) NS5A protein downregulates HCV IRES-dependent translation. J. Gen. Virol. 86:1015.
Yeh et al. (2005) Characterization of a HCV NS5A protein derived from a patient with hepatoma. Biochem. Biophys. Res. Commun. 327:516.
Beaulieu et al. (2004) Inhibitors of the HCV NS5B polymerase: new hope for the treatment of hepatitis C infections. Curr. Opin. Investig. Drugs. 5:838.
Gopalsamy et al. (2004) Discovery of pyrano[3,4-b]indoles as potent and selective HCV NS5B polymerase inhibitors. J. Med. Chem. 47:6603.
Summa et al. (2004) HCV NS5b RNA-dependent RNA polymerase inhibitors: from alpha, gamma-diketoacids to 4,5-dihydroxypyrimidine- or 3-methyl-5-hydroxypyrimidinonecarboxylic acids. Design and synthesis. J. Med. Chem. 47:5336.
Yannopoulos et al. (2004) HCV NS5B polymerase-bound conformation of a soluble sulfonamide inhibitor by 2D transferred NOESY. Bioorg. Med. Chem. Lett. 14:5333.